Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 3
1952 1
1960 1
1971 1
1976 1
1995 3
1996 2
1997 1
1998 2
1999 1
2000 3
2001 4
2002 3
2003 2
2004 6
2005 5
2006 4
2007 6
2008 12
2009 6
2010 5
2011 5
2012 2
2013 9
2014 5
2015 5
2016 5
2017 5
2018 3
2019 6
2020 2
2021 8
2022 7
2023 11
2024 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Results by year

Filters applied: . Clear all
Page 1
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, Havla J, Hellwig K, Hümmert MW, Jarius S, Kleiter I, Klotz L, Krumbholz M, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Trebst C, Tumani H, Warnke C, Wildemann B, Berthele A; Neuromyelitis Optica Study Group (NEMOS). Kümpfel T, et al. J Neurol. 2024 Jan;271(1):141-176. doi: 10.1007/s00415-023-11910-z. Epub 2023 Sep 7. J Neurol. 2024. PMID: 37676297 Free PMC article. Review.
Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial.
Reiff T, Eckstein HH, Mansmann U, Jansen O, Fraedrich G, Mudra H, Böckler D, Böhm M, Debus ES, Fiehler J, Mathias K, Ringelstein EB, Schmidli J, Stingele R, Zahn R, Zeller T, Niesen WD, Barlinn K, Binder A, Glahn J, Hacke W, Ringleb PA; SPACE-2 Investigators. Reiff T, et al. Lancet Neurol. 2022 Oct;21(10):877-888. doi: 10.1016/S1474-4422(22)00290-3. Lancet Neurol. 2022. PMID: 36115360 Clinical Trial.
Redefine photoprotection: Sun protection beyond sunburn.
van Bodegraven M, Kröger M, Zamudio Díaz DF, Lohan SB, Moritz RKC, Möller N, Knoblich C, Vogelsang A, Milinic Z, Hallhuber M, Weise JM, Kolbe L, Gallinger J, Graupner C, Klose H, Ulrich C, Meinke MC. van Bodegraven M, et al. Among authors: weise jm. Exp Dermatol. 2024 Jan;33(1):e15002. doi: 10.1111/exd.15002. Exp Dermatol. 2024. PMID: 38284193
Confirming the nature of autistic burnout.
Arnold SR, Higgins JM, Weise J, Desai A, Pellicano E, Trollor JN. Arnold SR, et al. Among authors: weise j. Autism. 2023 Oct;27(7):1906-1918. doi: 10.1177/13623613221147410. Epub 2023 Jan 13. Autism. 2023. PMID: 36637293
Towards the measurement of autistic burnout.
Arnold SR, Higgins JM, Weise J, Desai A, Pellicano E, Trollor JN. Arnold SR, et al. Among authors: weise j. Autism. 2023 Oct;27(7):1933-1948. doi: 10.1177/13623613221147401. Epub 2023 Jan 13. Autism. 2023. PMID: 36637292
Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, Havla J, Hellwig K, Hümmert MW, Jarius S, Kleiter I, Klotz L, Krumbholz M, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Trebst C, Tumani H, Warnke C, Wildemann B, Berthele A; Neuromyelitis Optica Study Group (NEMOS). Kümpfel T, et al. J Neurol. 2024 Jun;271(6):3702-3707. doi: 10.1007/s00415-024-12288-2. J Neurol. 2024. PMID: 38578500 Free PMC article. No abstract available.
CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients.
Zöphel S, Küchler N, Jansky J, Hoxha C, Schäfer G, Weise JJ, Vialle J, Kaschek L, Stopper G, Eichler H, Yildiz D, Moter A, Wendel P, Ullrich E, Schormann C, Rixecker T, Cetin O, Neumann F, Orth P, Bewarder M, Hoth M, Thurner L, Schwarz EC. Zöphel S, et al. Among authors: weise jj. Mol Cancer. 2024 Sep 28;23(1):210. doi: 10.1186/s12943-024-02123-7. Mol Cancer. 2024. PMID: 39342291 Free PMC article.
152 results